Anbio Biotechnology (NNNN)
NASDAQ: NNNN · Real-Time Price · USD
7.55
+0.14 (1.89%)
At close: Mar 28, 2025, 4:00 PM
7.51
-0.04 (-0.52%)
Pre-market: Mar 31, 2025, 4:03 AM EDT
Company Description
Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, Africa, and internationally.
It offers SARS-CoV-2 antigen rapid and SARS-CoV-2/influenza A/B antigen rapid tests; and lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, chemiluminescence immunoassay, and reverse-transcription polymerase chain reaction products.
It serves over-the-counter, point-of-care testing, and laboratory markets. The company was incorporated in 2021 and is based in Frankfurt am Main, Germany.
Anbio Biotechnology
| Country | Germany |
| Founded | 2021 |
| IPO Date | Feb 19, 2025 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 27 |
| CEO | Michael Lau |
Contact Details
Address: Wilhelm Gutbrod Str 21B Frankfurt am Main, 60437 Germany | |
| Phone | 49 16 0962 47281 |
| Website | anbio.com |
Stock Details
| Ticker Symbol | NNNN |
| Exchange | NASDAQ |
| Share Class | Class A Shares |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $5.00 |
| CIK Code | 0001982708 |
| ISIN Number | KYG0367B1059 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Michael Lau | Chief Executive Officer |
| Suki Song | Chief Financial Officer |
| Chris Tian | Chief Business Officer |
| Cany Xu | Director |
| Nancy Hartzler | Independent Director (Appointee), Chair of Compensation Committee |
| Kenneth Li | Independent Director (Appointee), Chair of Audit Committee |
| David Hsu | Independent Director (Appointee), Chair of Nominating Committee |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 21, 2025 | 6-K | Report of foreign issuer |
| Feb 19, 2025 | 424B4 | Prospectus |
| Feb 18, 2025 | EFFECT | Notice of Effectiveness |
| Feb 18, 2025 | CERT | Certification by an exchange approving securities for listing |
| Feb 14, 2025 | 8-A12B | Registration of securities |
| Feb 10, 2025 | F-1/A | [Amend] Registration statement for certain foreign private issuers |
| Jan 24, 2025 | F-1/A | [Amend] Registration statement for certain foreign private issuers |
| Jan 22, 2025 | FWP | Free Writing Prospectus |
| Jan 10, 2025 | F-1/A | [Amend] Registration statement for certain foreign private issuers |
| Dec 31, 2024 | F-1 | Registration statement for certain foreign private issuers |